Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

Guggenheim analyst Michael Schmidt raised the firm’s price target on Exelixis (EXEL) to $42 from $33 and keeps a Buy rating on the shares.

EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III drugs for Oropharyngeal Cancer have a 17% phase ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer.

Brookline Capital Markets initiated coverage of Exelixis (NASDAQ:EXEL) with a buy rating, highlighting the company's revenue potential. The investment firm said it sees Exelixis's (NASDAQ:EXEL ...

The company's focus is now on its drug zanzalintinib, which is currently undergoing trials for colorectal cancer. However, BMO Capital Markets and BofA Securities have both downgraded Exelixis due to ...